POTENTIAL PROGNOSTIC ROLE OF IMMUNE SYSTEM ACTIVATION MARKER NEOPTERIN IN PATIENTS WITH TYPE 2 DIABETES

Basit Öğe Kaydı
dc.authoridÜnüvar, Songül/0000-0001-8454-490X
dc.authorwosidÜnüvar, Songül/ABH-5516-2020
dc.contributor.authorUnuvar, Songul
dc.contributor.authorTanriverdi, Zubeyde
dc.contributor.authorAslanhan, Hamza
dc.date.accessioned2024-08-04T20:44:30Z
dc.date.available2024-08-04T20:44:30Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: An increase in neopterin concentrations is known in some pathologies due to interferon-gamma (INF-gamma) activation. These include viral and bacterial infections, autoimmune diseases, metabolic diseases, psychiatric disorders, tissue and organ rejections, and different malignancies. The aim of this study was to evaluate the role of neopterin as a prognostic biomarker in type 2 diabetes, which is a metabolic disease with a high worldwide prevalence. Methods: The study included a total of one hundred thirty-nine individuals including one hundred and six patients admitted to a family medicine outpatient clinic and diagnosed with type 2 diabetes and thirty-three healthy volunteers. Serum neopterin concentrations were measured using the enzyme-linked immunosorbent assay. Results: Serum neopterin levels significantly increased in type 2 diabetes patients, compared to the control group (p<0.001). Conclusions: Early diagnosis of diabetes and determination of the appropriate therapeutic options are of utmost importance, as diabetes is also associated with other systemic diseases. The risk of developing secondary diseases is high in untreated patients. Our study results suggest that serum neopterin may be a useful biomarker in patients with type 2 diabetes.en_US
dc.identifier.doi10.2478/jomb-2018-0004
dc.identifier.endpage469en_US
dc.identifier.issn1452-8258
dc.identifier.issn1452-8266
dc.identifier.issue4en_US
dc.identifier.pmid30584406en_US
dc.identifier.scopus2-s2.0-85047093072en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage465en_US
dc.identifier.urihttps://doi.org/10.2478/jomb-2018-0004
dc.identifier.urihttps://hdl.handle.net/11616/98292
dc.identifier.volume37en_US
dc.identifier.wosWOS:000442543800009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSciendoen_US
dc.relation.ispartofJournal of Medical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecttype 2 diabetesen_US
dc.subjectmetabolic diseasesen_US
dc.subjectneopterinen_US
dc.subjectimmune system activationen_US
dc.subjectinterferon-gammaen_US
dc.titlePOTENTIAL PROGNOSTIC ROLE OF IMMUNE SYSTEM ACTIVATION MARKER NEOPTERIN IN PATIENTS WITH TYPE 2 DIABETESen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu